0013536 2024 RIV NL eng J
Štach, Martin - Pytlík, Robert - Šmilauerová, Kristýna - Rychlá, Jana - Mucha, Martin - Musil, Jan - Koladiya, Abhishek - Nemec, Matěj - Petráčková, Martina - Kaštánková, Iva - Pecherková, Pavla - Šrámková, L. - Polgárová, K. - Trněný, M. - Lesný, Petr - Vydra, Jan - Otáhal, Pavel^G
Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome.
Pathology and oncology research. Vol. 29, no. April (2023), art. no. 1610914. ISSN 1219-4956
Grant: Ministerstvo zdravotnictví NU22-05-00374
Institucionální podpora: RVO:00023736
Klíčová slova: B-cell lymphoma and leukemia * CAR-T cells * Kymriah
Cite Score: 6.300, rok: 2023; SJR: 0.716, rok: 2023; IF: 2.3, rok: 2023
DOI: 10.3389/pore.2023.1610914

Anotace: Tisagenlecleucel (tisa-cel) is a CD19-specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed a group of patients diagnosed with childhood B-ALL (n = 5), adult B-ALL (n = 2), and DLBCL (n = 25) who were treated with tisa-cel under non-clinical trial conditions. The goal was to determine how the intensive pretreatment of patients affects the produced CAR-T cells, their in vivo expansion, and the outcome of the therapy. Multiparametric flow cytometry was used to analyze the material used for manufacturing CAR-T cells (apheresis), the CAR-T cell product itself, and blood samples obtained at three timepoints after administration. We present the analysis of memory phenotype of CD4/CD8 CAR-T lymphocytes (CD45RA, CD62L, CD27, CD28) and the expression of inhibitory receptors (PD-1, TIGIT). In addition, we show its relation to the patients' clinical characteristics, such as tumor burden and sensitivity to prior therapies.